Oral IL23 Receptor Blocker Meets Phase 3 Psoriasis Endpoints

Johnson & Johnson disclosed November 6 Phase 3 ICONIC-ASCEND data for oral IL-23 receptor antagonist icotrokinra in moderate-to-severe plaque psoriasis. Week-16 PASI 90 was 55.2% versus 3.6% on placebo and IGA 0/1 was 70.4%…




